Global Hospital Injectable Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Hospital Injectable Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Injectables refer to drug delivery system which acts as an alternative to oral drugs. As injectables are rapidly inserted into the human body using a syringe, they bypass the first-pass metabolism. In tablet form, some of the drugs become ineffective as they get dismantled in the stomach owing to the digestive enzymes. Generic injectables are pharmaceutical drugs that are bio-equivalent of a branded injectable in terms of dosage, strength, performance, intended use, side-effects and route of administration.

According to our (Global Info Research) latest study, the global Hospital Injectable Drugs market size was valued at US$ 43750 million in 2023 and is forecast to a readjusted size of USD 60070 million by 2030 with a CAGR of 4.7% during review period.

In 2019, North America held the main share in global hospital injectable drugs market,with the propotion of 35%,Europe followed loosely ,at the propotion of 33%.

Hospira (Pfizer Inc.) occupied the biggest global hospital injectable drugs market share(13%), Fresenius Kabi followed closely at the propotion of 13%, Baxter and Sichuan Kelun Pharmaceutical also played a virtal role in the market.

This report is a detailed and comprehensive analysis for global Hospital Injectable Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Hospital Injectable Drugs market size and forecasts, in consumption value ($ Million), 2019-2030

Global Hospital Injectable Drugs market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Hospital Injectable Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030

Global Hospital Injectable Drugs market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Hospital Injectable Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Hospital Injectable Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hospira (Pfizer Inc.), Baxter, Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Otsuka, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Hospital Injectable Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Hospital Injectable Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Generic Sterile Injectables
Sterile Intravenous (IV) Solutions

Market segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases

Market segment by players, this report covers
Hospira (Pfizer Inc.)
Baxter
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Otsuka
B.Braun
JW Life Science
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Sichuan Kelun Pharmaceutical
Cisen Pharmaceutical
Shijiazhuang No. 4 Pharmaceutical
Shandong Hualu Pharmaceutical
CR Double-Crane

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Hospital Injectable Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Hospital Injectable Drugs, with revenue, gross margin, and global market share of Hospital Injectable Drugs from 2019 to 2024.

Chapter 3, the Hospital Injectable Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Hospital Injectable Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Hospital Injectable Drugs.

Chapter 13, to describe Hospital Injectable Drugs research findings and conclusion.